Capreomycin Sulfate

Sold as Capastat Sulfate. Every FDA application for this active ingredient: 1 branded and 2 generic.

As of Nov 15, 2026, FDA lists 3 applications for Capreomycin Sulfate (sold as Capastat Sulfate), first approved Jun 2, 1971, with 0 new uses approved and 0 published complete response letters.

First approved: Jun 2, 1971
Applications: 3
New uses approved: 0
Complete response letters: 0

Clinical Trials

1 open or ongoing study names this ingredient as an intervention, including as a comparator; newest first. See all

Study	Phase	Status	Posted
Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With TuberculosisTuberculosis · Beijing Children's Hospital	—	Recruiting	Aug 10, 2018

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Jun 2, 1971	Capastat SulfateNDA 50095	Epic Pharma LLC	46	Discontinued
Nov 27, 2017	Capreomycin SulfateANDA 202634	Pharmobedient	2	Discontinued
Oct 18, 2018	Capreomycin SulfateANDA 204796	Hisun Pharm Hangzhou	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA